*AGENDA*

***Uniform Formulary Beneficiary Advisory Panel (UF BAP)***
***For the May 2024 Department of Defense Pharmacy and Therapeutics Committee Meeting***
***June 26, 2024 at 10:00 AM Eastern Daylight Time***

***Virtual Meeting***

- **General session starts at 10:00 AM Eastern Daylight Time (Administrative meeting preceding)**

- **Roll Call**

- **Therapeutic Class Reviews**

  *Members of the Defense Health Agency (DHA) Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effective analyses along with the Department of Defense (DoD) Pharmacy & Therapeutics Committee (P&T) recommendations for the Uniform Formulary (UF) and any recommended complete exclusion candidates.*

  *The DoD P&T Committee made recommendations for the following drugs/drug classes during the May 2024 meeting.*

- **Drug Class Reviews**
  - *Insulins: Basal Insulin Analogs*
  - *Weight Loss Agents*
  - *Pulmonary II Agents: Inhaled Corticosteroids (ICS) Subclass*

- **Newly Approved Drugs per 32 CFR 199.21(g)(5)**
  - *birch triterpenes 10% (w/w) topical gel (Filsuvez)—Skin Preps for epidermolysis bullosa*
  - *bosutinib capsules (Bosulif)—Oncological Agents for chronic myelogenous leukemia (CML)*
  - *budesonide 2 mg/10 mL oral suspension (Eohilia)—Gastrointestinal-1 Agent for eosinophilic esophagitis (EoE)*
  - *cyclosporine 0.1% ophthalmic solution (Vevye)—Ophthalmic agent for dry eye disease*
  - *eflornithine tablets (Iwilfin)—Oncological Agent for neuroblastoma*
  - *eltrombopag 9 mg, 18 mg, 35 mg, 54 mg tablets (Alvaiz)—Hematological Agents: platelets, for chronic immune thrombocytopenia (ITP)*

- *eplontersen injection (Wainua)—Miscellaneous Neurological Agent for hereditary transthyretin-mediated amyloidosis*
- *infliximab-dyyb injection (Zymfentra)—Targeted Immunomodulatory Biologics (TIBs): tumor necrosis factor (TNF) inhibitor for ulcerative colitis and Crohn's disease*
- *iptacopan (Fabhalta)—Hematological Agent for paroxysmal nocturnal hemoglobinuria (PNH)*
- *nedosiran injection (Rivfloza)—Nephrology Agent for hyperoxaluria type 1 (PH1)*
- *omalizumab autoinjector (Xolair)—Atopy Agents; new formulation and indication for reduction of allergic reactions (Type I) in patients with IgE-mediated food allergy*
- *roflumilast 0.3% topical foam (Zoryve)—Psoriasis Agent*
- *sitagliptin free base (Zituvio and Zituvio authorized generic)—Diabetes Non-Insulin: (DPP-4) Inhibitor for diabetes*
- *vamorolone oral suspension (Agamree)—Corticosteroids – Immune Modulator for Duchenne Muscular Dystrophy*
- *zilucoplan injection (Zilbrysq)—Miscellaneous Neurological Agent for myasthenia gravis*

➢ **Utilization Management Issues**

- **Prior Authorization (PA) Criteria—New Manual Prior Authorization (PA) Criteria**
  - *Anticonvulsants-Antimania Agents: brivaracetam tablets and oral solution (Briviact)*
- **PA Criteria—Manual PA Criteria for Newly Approved Drugs Not Subject to 32 CFR 199.21(g)(5)**
  - *Narcotic Analgesics and Combinations: tramadol 25 mg tablets*
- **PA Criteria—Updated PA Criteria for New FDA-Approved Indications**
  - *Atopy Agents: dupilumab (Dupixent)*
  - *Oncological Agents: Breast Cancer: alpelisib (Piqray)*
  - *Oncological Agents: Lung Cancer: alectinib (Alecensa)*
  - *Oncological Agents: erdafitinib (Balversa)*
- **PA Criteria—Updated PA Criteria for Reasons Other Than New Indications**
  - *Oncological Agents: Lung Cancer: sotorasib (Lumakras)*
  - *Targeted Immunomodulatory Biologics (TIBs): Tumor Necrosis Factor Inhibitors (TNFs): golimumab (Simponi)*

- *TIBs: adalimumab (Humira), etanercept (Enbrel), ixekizumab (Taltz), ustekinumab (Stelara), and secukinumab (Cosentyx)*
- *Growth Hormone Stimulating Agents*
- *Corticosteroid Immune Modulators: deflazacort (Emflaza)*
- *Gastrointestinal-2 Agents: sacrosidase oral solution (Sucraid)*

➢ **Removal of PA Criteria—Diabetes Non-Insulin Drugs - Sodium-Glucose Co-Transport 2 (SGLT-2) Inhibitors**

- *Diabetes Non-Insulin: SGLT-2 Inhibitors: empagliflozin/linagliptin (Glyxambi) and empagliflozin/ linagliptin/metformin XR (Trijardy XR)*

➢ **Brand Over Generic PA Authorization and Tier 1 copay**

- *Attention Deficit Hyperactivity Disorder (ADHD) Agents: Lisdexamfetamine (Vyvanse)*

➢ **Re-evaluation of Nonformulary Generics**

- *Calcium Channel Blockers (CCBs)*
  - *diltiazem 24h extended release (ER) tablets (Cardizem LA generics)*
  - *isradipine (Dynacirc generics)*
  - *nicardipine (Cardene generics)*
  - *nisoldipine 24h ER tablets, controlled release (Sular generics)*
  - *verapamil 24h sustained release pellet-filled capsules (Verelan generics)*
- *High- and medium-potency "hair-friendly" topical corticosteroids (solutions, foams, shampoos)*
  - *betamethasone valerate 0.12% foam (Luxiq, generics)*
  - *clobetasol propionate/emollient 0.05% foam (Olux-E, generics)*
  - *clobetasol propionate 0.05% shampoo/cleanser kit (Clodan Kit)*
  - *halobetasol propionate 0.05% foam (Lexette, generic)*
- *High- and medium-potency topical corticosteroids (creams, gels)*
  - *fluocinonide 0.1% cream (Vanos, generics)*
  - *halobetasol propionate 0.05% cream (Ultravate, generics)*
- *Proton Pump Inhibitors (PPIs)*
  - *rabeprazole tablets*
  - *esomeprazole capsules*
  - *lansoprazole capsules*

- *Selective Serotonin Reuptake Inhibitors (SSRIs)*
  - *fluoxetine 10 mg tablets*
  - *fluoxetine 20 mg tablets*

➢ **Panel Discussions**

*The UF BAP members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will concur or non-concur on the recommendations of the DoD P&T Committee concerning the establishment of the UF and subsequent recommended changes. The Panel will provide comments on their vote as directed by the Panel Chairman. Comments to the Director, DHA, or their designee will be considered before making a final UF decision.*